Head-To-Head Comparison: Lunai Bioworks (NASDAQ:LNAI) vs. NexImmune (OTCMKTS:NEXI)

Lunai Bioworks (NASDAQ:LNAI) and NexImmune (OTCMKTS:NEXI) are both manufacturing companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Institutional and Insider Ownership

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 9.9% of NexImmune shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Comparatively, 14.9% of NexImmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Lunai Bioworks has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, NexImmune has a beta of -2286.43, meaning that its stock price is 228,743% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Lunai Bioworks and NexImmune, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1	0	0	0	1.00
NexImmune	0	0	0	0	0.00

Profitability

This table compares Lunai Bioworks and NexImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-360.31%
NexImmune	N/A	N/A	N/A

Valuation & Earnings

This table compares Lunai Bioworks and NexImmune”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01 million	($0.07)	-7.79
NexImmune	N/A	N/A	-$32.34 million	($18.29)	0.00

Lunai Bioworks is trading at a lower price-to-earnings ratio than NexImmune, indicating that it is currently the more affordable of the two stocks.

Summary

NexImmune beats Lunai Bioworks on 5 of the 9 factors compared between the two stocks.

About Lunai Bioworks

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.